|
|
|
| The Correlation of Serum IL-17 and TLR4 in Patients with COPD and Their Correlation with FEV1%pred mMRC Grading and CAT Score |
| SUN Yin, WEI Haiyan |
| Chengde Central Hospital, Hebei Chengde 067000, China |
|
|
|
|
Abstract Objective: To investigate the expression of serum interleukin-17 (IL-17) and toll-like receptor 4 (TLR4) in patients with chronic obstructive pulmonary disease (COPD) and their correlation with the forced expiratory volume in the first second as a percentage of the predicted value (FEV1%pred), the modified British medical research council (mMRC grading), and the COPD Assessment Test (CAT) score.Methods: The levels of serum IL-17 and TLR4 in patients in three groups [COPD group, healthy smoking control group (C1), healthy non-smoking control group (C2), 80 cases in each group] were measured by ELISA method, and analyzed their relevance with FEV1%pred, mMRC grading, and CAT score. Results: The levels of serum IL-17 and TLR4 in patients of COPD group were significantly higher than those in health controls (C1 group and C2 group) (P<0.05). Serum IL-17 in group C1 was significantly higher than that in group C2 (P<0.05); serum TLR4 in group C1 was significantly lower than that in group C2 (P<0.05). The levels of serum IL-17 and TLR4 in the patients of COPD group were negatively correlated with FEV1%pred (P<0.05). The levels of serum IL-17 and TLR4 in COPD group were positively correlated with mMRC grading and CAT score (P<0.05). There was a positive correlation between the serum IL-17 level and TLR4 level in the patients of COPD group (P<0.05). Conclusion: The levels of IL-17 and TLR4 in patients with chronic obstructive pulmonary disease were significantly up-regulated, and they were positively correlated with the severity of the disease.
|
|
|
|
|
|
[1] Vogelmeier CF,Criner GJ,Martinez FJ,et al.Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 Report. GOLD Executive Summary[J]. Am RespirCrit Care Med, 2017, 195(5): 557~582.
[2] 中华医学会,中华医学会杂志社,中华医学会全科医学分会,等.慢性阻塞性肺疾病基层诊疗指南(2018年)[J].中华全科医师杂志,2018,17(11):856~870.
[3] 曹路,高宝安,官莉,等.慢阻肺患者血清中组蛋白去乙酰化酶2 IL-1βIL-6及IL-17A的水平及临床意义[J].河北医学,2019,25(10):1585~1588.
[4] 凡尔克·艾合买提江,夏衣达·吐尔逊,郭文涛,等.TLR4和IRF7在宫颈病变组织中的表达及临床病理学意义[J].新疆医科大学学报,2019,42(12):1559~1563,1568.
[5] Rahimifard M, Maqbool F, Moeini-Nodeh S, et al. Targeting the TLR4 signaling pathway by polyphenols: a novel therapeutic strategy for neuroinflammation[J]. Ageing Res Rev, 2017, 36(7): 11~19.
[6] Tripathi PM, Kant S, Yadav RS, et al. Expression of toll-like receptor 2 and 4 in peripheral blood neutrophil cells from patients with chronic obstructive pulmonary disease[J]. Oman Med, 2017,32(6):477~485.
[7] 王旭,邹新中,张彩娣,等.COPD肺部炎症反应与血管重构中PPAR-α及TLR4表达的关系[J].中国老年学杂志,2018,38(12):3045~3047.
[8] 李泽伦,许浦生,崔志新,等.慢性阻塞性肺疾病患者血清IL-10、TGF-β1与FEV1%、FEV1/FVC及CAT评分的相关性分析[J].临床肺科杂志,2017,22(9):1577~1580. |
|
|
|
2020, Vol. 26 
